Efficient regioselective three-component domino synthesis of 3-(1,2,4-Triazol-5-yl)-1,3-thiazolidin-4-ones as potent antifungal and antituberculosis agents

Article abstract of DOI:10.1002/ardp.201100001

In research for promising antibacterial and antifungal compounds, a series of 2-aryl 3-[1,2,4]triazol-5-yl 4-thiazolidinones 1 were synthesized by a domino reaction of 5-amino-1H-[1,2,4]triazoles 3, aromatic aldehydes, and α-mercaptoacids in boiling tolue

Full text of DOI:10.1002/ardp.201100001

Arch. Pharm. Chem. Life Sci. 2011, 344, 821–829
821
Full Paper
Efficient Regioselective Three-Component Domino Synthesis
of 3-(1,2,4-Triazol-5-yl)-1,3-thiazolidin-4-ones as Potent
Antifungal and Antituberculosis Agents
Serry A. El Bialy1, Maria M. Nagy2, and Hamdy M. Abdel-Rahman3
1 Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura,
Egypt
2 Department of Applied and Environmental Microbiology, Georgia State University Atlanta, GA, USA
3 Department of Medicinal Chemistry, Faculty of Pharmacy, Assiut University, Assiut, Egypt
In research for promising antibacterial and antifungal compounds, a series of 2-aryl 3-[1,2,4]triazol-5-
yl 4-thiazolidinones 1 were synthesized by a domino reaction of 5-amino-1H-[1,2,4]triazoles 3, aromatic
˚
aldehydes, and a-mercaptoacids in boiling toluene in the presence of molecular sieves 4 A. Of the
twenty novel 3-[1,2,4]triazol-5-yl 4-thiazolidinone derivatives, four compounds 2-benzo[d][1,3]dioxol-6-
yl-3-[(3-morpholin-4-yl)-1H-1,2,4-triazol-5-yl)]-1,3-thiazolidin-4-one (1i), 2-(4-chlorophenyl)-5-methyl-3-[3-
(4-methylpiperazin-1-yl)-1H-1,2,4-triazol-5-yl]-1,3-thiazolidin-4-one (1p), 2-benzo[d][1,3]dioxol-6-yl-3-[3-
(4-methylpiperazin-1-yl)-1H-1,2,4-triazol-5-yl]-1,3-thiazolidin-4-one (1s), 2-benzo[d][1,3]dioxol-6-yl-5-
methyl-3-[3-(4-methylpiperazin-1-yl)-1H-1,2,4-triazol-5-yl]-1,3-thiazolidin-4-one (1t) exhibited MICs of
4 mg/mL or less versus Mycobacterium tuberculosis. Moreover, these compounds were screened
against Candida albicans. Compounds 1p, 1s gave MICs of 1 mg/mL or less, and were fungicidal.
Finally, compound 1s was evaluated against an expanded fungal panel and showed good activity
against Cryptococcus neoformans. In addition, compound 1s also appeared to be fungicidal against
Aspergillus arrhizus, with MIC <1 mg/mL.
Keywords: 5-Amino-1H-[1,2,4]triazoles / Antifungal agents / Antituberculosis agents / Domino reaction /
4-Thiazolidinones
Received: January 2, 2011; Revised: February 16, 2011; Accepted: February 22, 2011
DOI 10.1002/ardp.201100001
Introduction
In such reactions, three or more reactants are employed
in a single reaction vessel to obtain new products constitutive
of all components [5]. On the other hand, the domino
reactions are defined as a special case of MCRs that could
form several bonds in one sequence without isolating
the intermediates, changing the reaction conditions, or
adding reagent [6, 7]. Therefore, these types of reactions
would allow an ecologically and economically favorable pro-
duction [8].
The necessity for more potent antimicrobial agents has
become vital because of emerged resistance to the currently
used antibiotics. Patients suffering from debilitating diseases
such as neoplasia who need long term parenteral nutrition
may suffer from systemic infections caused by resistant
microorganisms [1].
The multi-component reactions (MCRs) are gaining import-
ance in organic and medicinal chemistry [2]. MCRs strategies
offer significant advantages over conventional linear-type
synthesis [3] through increased contribution on speed,
diversity and efficiency in the drug discovery process [4].
4-Thiazolidinone [9] derivatives possess antibacterial [10–13],
antifungal [14–19], and antituberculosis [20, 21] activities.
4-Thiazolidinones have been reported as novel inhibitors
of the bacterial enzyme Mur B [22] which is essential in cell
wall biosynthesis.
Cell wall biosynthesis in bacteria involves the assembly of
peptidoglycan which serves as a critical structural unit of
the cell wall by maintaining the osmotic integrity of the
cell. The biosynthesis of peptidoglycan proceeds from UDP
Correspondence: Serry A. El Bialy, Department of Chemistry, Georgia
State University, Atlanta, GA 30303, USA.
E-mail: sbialy65@yahoo.com
Fax: þ1-404- 413-5505
ß 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

822
S. A. El Bialy et al.
Arch. Pharm. Chem. Life Sci. 2011, 344, 821–829
N-acetylglucosamine with the two-step synthesis of UDP-N-
acetylmuramic acid catalyzed by the enzymes MurA and
MurB. MurA facilitates the addition of an enolpyruvyl moiety
from phosphoenolpyruvate to the 3-hydroxyl of UDP-N-ace-
tylglucosamine. MurB is responsible for the reduction of the
enol ether to the lactyl ether, utilizing 1 equivalent of NADPH
and a solvent-derived proton [23].
This study was initiated by the synthesis of the starting
materials, 5-amino-1H-3-substituted (1,2,4)-triazoles in two
steps. Therefore, N-cyanocarbonimidodithioic acid dimethyl
ester 5 reacted smoothly with one molar equiv. of cyclic
amines in boiling acetonitrile to give the corresponding
isothiourea derivative 4. Without the isolation of isothiour-
eas, a slight excess of hydrazine was added and the mixture
was refluxed till complete evolution of methyl mercaptan
furnishing 5-amino-1H-3-substituted (1,2,4)-triazoles in excel-
lent yields [28].
As part of a research program directed to drug discovery of
antimicrobial agents [24–27] and due to the previously
reported antimicrobial activity of 4-thiazolidinones we
decided to synthesize a series of thiazolidinone derivatives
to investigate structure activity relationship (SAR) and their
antimicrobial profiles. We report here the synthesis of twenty
novel 3-(1,2,4)-triazol-5-yl-1,3-thiazolidin-4-ones derivatives
using three-component domino reaction and their evaluation
against various microbial agents including Candida albicans
A39, Aspergillus fumigatus (strain 168.95), and Mycobacterium
tuberculosis H37Rv.
Practically, 4-thiazolidinone derivatives 1 were obtained
using a three-component domino reaction. Therefore, a mix-
ture of 5-amino-1H-(1,2,4)-triazoles 3, the appropriate alde-
hydes and a-mercaptoacids was reacted in the presence of
˚
molecular sieves (4 A) in toluene at 858C to give 3-(1,2,4-
triazol-5-yl)-1,3-thiazolidin-4-one derivatives 1 (Scheme 1).
The reaction pathway involves the in-situ formation of
intermediate 5-triazolylimines 2 by condensation of the
amine 3 and the appropriate aldehydes. The next step
involves the nucleophilic attack of the thiol group to the
imine carbon–nitrogen double bond giving the intermediate
6, which has two possible nucleophilic nitrogens for reaction
with the thioacid carboxyl group. This would lead to the
formation of either 1,2,4-triazol-5-yl-1,3-thiazolidin-4-one 1
or [1,2,4]triazolo[5,1-d][1,3,5]thiadiazepin-8(7H)one ring 7. It
seems of much interest to note that the present cyclization
proceeds regiospecifically to exclusively give 4-thiazolidi-
none. This is in striking contrast to the reported formation
of [1,2,4]triazolo[5,1-d][1,3,5]thiadiazepin-8(7H)one ring 7 in an
analogous reaction with 3-amino pyrazole [29, 30] (Scheme 2).
It is worthy to note that the product obtained from a-
mercaptopropionic acid gave a mixture of cis and trans iso-
Results and discussion
Chemistry
Our strategy for the synthesis of 3-(1,2,4-triazol-5-yl)-1,3-thi-
azolidin-4-ones is based upon the cycloaddition reaction of
a-mercaptoalkalonic acids to an imine group in a three-
component domino reaction.
The retrosynthetic study of this strategy (Fig. 1) revealed
that the 3-(1,2,4)-triazol-5-yl-1,3-thiazolidin-4-ones 1 could be
obtained from the reaction of 5-amino-1H-(1,2,4)-triazoles 3,
aromatic aldehydes and a-mercaptoacids without isolation of
Schiff‘s bases 2 (c.f. the linear type synthesis). The amine 3
could be accessible by the reaction of cyanocarbonimidodi-
thioic acid dimethyl ester (5) with one molar equivalent of an
appropriate cyclic amine followed by the reaction with
hydrazine hydrate (NH2NH2 ꢀ H2O) without isolation of iso-
thioureas 4.
1
mers. H-NMR spectra of such mixtures showed that a 2-Hz
coupling between hydrogens on carbons 2 and 5 corresponds
to the cis-form. The cis-form is better able to adopt a ‘‘W’’
configuration favoring indirect coupling which is often
R1
R2
O
1
OHC
R2
R1
N
NH
SH
N
NH
HO
5
3
R2
R1
R3
N
N
N
2
N
N
N
N
S
4
5
X
X
O
1
R3
2
NH
SMe
N NCN
MeS
N
N
NH2
NCN
X
X
MeS
3
4
5
Figure 1. Retrosynthetic study of 3-[1,2,4]-
triazol-5-yl 4-thiazolidinones.
ß 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.archpharm.com

Arch. Pharm. Chem. Life Sci. 2011, 344, 821–829
Efficient Regioselective Three-Component Domino Synthesis . . .
823
R1
N
NH
NH2
R2
OHC
R2
R1
X
NH
MeS
MeS
N
NH
N
N
NCN
X
O
NH2NH2
N
N
N
S
SH
HO
3a X=O
5
1
X
b
X=NMe
R3
O
R3
Molecular sieve Å4
toluene
1
_
(65 91%)
X
R1
R2
R3 Yield (%)
1
X
R1
R2
R3 Yield (%)
83
86
91
69
65
67
H
H
a
b
c
O
O
O
H
H
H
H
k
NMe
NMe
H
H
H
H
H
Me
H
Me
H
H
l
Me
m
NMe Me
88
79
65
77
Me
H
Me
H
d
e
f
O
O
O
O
O
O
O
Me
Cl
Cl
H
H
n
o
p
q
r
NMe Me
NMe Cl
NMe Cl
H
H
H
Me
H
81
73
79
69
71
H
H
H
Me
H
73
78
79
73
70
g
h
I
OMe H
OMe H
-OCH2O-
-OCH2O-
NMe OMe
NMe OMe
NMe -OCH2O-
NMe -OCH2O-
Me
H
Me
H
s
t
Scheme 1. Synthesis of 3-[1,2,4]triazol-5-yl-
4-thiazolidinones.
J
Me
Me
N
NH
A
N
N
N
O
HO
B
X
S
O
N
N
N
NH
A
N
1
S
N
H
N
N
N
N
O
X
X
2
N
N
6
S
N
N
N
B
H
Scheme 2. Mechanism of formation of 3-
[1,2,4]triazol-5-yl 4-thiazolidinones.
X
7
invoked to rationalized hydrogen spin-spin splitting across
four single bonds [31].
Subsequently, compound ls showed excellent antifungal
activity against A. fumigatus with a MIC value of <1 mg/mL.
Across the broad sample, compound 1s showed impressive
activity against all three organisms with a MIC value of
ꢁ1.0 mg/mL and MFC levels of ꢁ1.0 mg/mL against both fun-
gal species C. albicans and Aspergillus fumigatus. Finally, it is of
interest to note that the methylenedioxy substituted com-
pounds exhibited the greatest antimicrobial activity.
The replacement of the morpholine with N-methyl piprazine
on methylenedioxy substituted compounds lowers the
activity as antifungal but without effect on the antitubercu-
losis activity. Chloro substituted compounds with N-methyl
piperazine moiety exhibited similar antimicrobial activity to
methylenedioxy substituted compounds.
Biology
2-Aryl 3-(1,2,4-triazol-5-yl)-1,3-thiazolidin-4-ones 1a–t were
screened for their potential antifungal activities against
Candida albicans and Aspergillus fumigates. These were also
tested against Mycobacterium tuberculosis for their antitubercu-
losis activity. The antimicrobial data for these compounds are
summarized in Table 1. The greatest activity among the
twenty compounds 1a–t was found for (1i, 1p, 1s, 1t) which
showed good in-vitro activity against C. albicans with MIC
values of <4 mg/mL. Compounds 1p and 1s were fungicidal
against C. albicans with MIC values of <1 mg/mL in compari-
son with fluconazole, a known antibiotic possessing a MIC
value of 0.25 mg/mL. Compounds 1i, 1n, 1s showed good
in-vitro activity against M. tuberculosis with MIC values of
<1 mg/mL. Compounds 1m, 1n, lp, lq and lt showed activity
against A. fumigatus producing MIC values of 10 mg/mL.
Next in an expanded fungal panel, summarized in Table 2,
1s was screened for MIC80, MIC100 and MFC concentrations
against seven C. albicans isolates, five A. fumigates isolates and
three isolates of Fusarium solani, Rhizopus arrhizus and
Cyrptococcus neoformans. The compound 1s showed MIC80 of
ß 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.archpharm.com

824
S. A. El Bialy et al.
Arch. Pharm. Chem. Life Sci. 2011, 344, 821–829
Table 1. MIC and MFC values of 2-aryl 3-[1,2,4]triazolyl 4-thiazolidinone compounds.
Compound
No
C. albicans
A. fumigatus
M. tuberculosis
X
R1
R2
R3
MIC
(mg/mL)
MFC
(mg/mL)
MIC
(mg/mL)
MFC
(mg/mL)
MIC
(mg/mL)
1a
1b
1c
1d
1e
1f
1g
1h
1i
1j
1k
1l
1m
1n
1o
O
O
O
O
O
O
O
O
O
H
H
CH3
CH3
Cl
Cl
OCH3
OCH3
H
H
H
H
H
H
OCH3
OCH3
H
CH3
H
CH3
H
CH3
H
CH3
H
CH3
H
CH3
H
CH3
H
CH3
H
10
25
12.5
nt
100
50
25
nt
50
nt
nt
100
2.08
25
10
nt
>100
10
100
10
100
100
100
nt
100
100
>100
nt
16
8
3.13
1.56
1.56
ꢁ 6.25
nda
16
25
nt
nt
>100
>100
10
1.04
12.2
10
nt
10
10
100
100
100
33.4
100
100
nt
10
10
100
10
>100
>100
100
33.4
100
100
nt
>100
100
nt
–OCH2O–
–OCH2O–
ꢁ1
O
4
NCH3
NCH3
NCH3
NCH3
NCH3
NCH3
NCH3
NCH3
NCH3
NCH3
H
H
CH3
CH3
Cl
Cl
OCH3
OCH3
H
H
H
H
H
H
OCH3
OCH3
8
nt
nt
ꢁ1
100
ꢁ1
nt
1p
1q
1r
1s
>100
>100
nt
2
nt
8
10
>100
>100
ꢁ1
10
CH3
H
CH3
100
ꢁ1
>100
ꢁ1
–OCH2O–
–OCH2O–
ꢁ1
ꢁ1
1t
3.12
0.25
6.25
NA
10
10
3.13
Fluconazole
Voriconazole
Rifampin
13.5
NA
0.062
a
No activity observed at 6.25 mg/mL
NA: Not active
nt: Not tested
Table 2. Evaluation of 1s against an expanded fungal panel.
Genus
Species
Isolate No.
MIC (80%)
MIC (100%)
MFC
Candida
Candida
Candida
Candida
Candida
Candida
Candida
Aspergillus
Aspergillus
Aspergillus
Aspergillus
Aspergillus
Fusarium
Rhizopus
Cryptococcus
albicans
albicans
albicans
albicans
albicans
116.98
159.95
149.97
156.97
126.97
117.00
A39
168.95
182.99
119.00
165.86
153.90
152.89
117.89
H99
1.56
0.79
0.78
1.56
1.56
0.78
1.56
10
3.12
3.12
50
3.12
3.12
0.78
1.56
1.56
1.58
1.56
3.15
3.12
3.12
1.56
50
50
50
50
50
>100
3.12
6.25
>100
3.12
25
albicans
albicans
25
fumigatus
fumigatus
fumigatus
fumigatus
fumigatus
solani
>100
>100
>100
>100
>100
50
50
1.56
1.56
arrhizus
neoformans
1.56
>100
3 mg/mL values against all tested strains except, A. fumigatus
isolates 168.95 and 153.90. It has a MIC100 of 3 mg/mL or less
against all C. albicans and C. neoformans strains. Also, ls showed
MFC activity at 3 mg/mL against C. albicans 159.995 and 126.97
and Rhizopus arrihizus. Subsequently, the results show that
sample ls shows great potential as an antifungal and anti-
tuberculosis agent and thus it warrants further study.
In conclusion, the three-component domino reaction
described in this paper is a very regioselective, facile and
practical method for the synthesis of 4-thiazolidinone. The
ease of the reaction procedure, the work-up and the signifi-
cantly high yields prove this procedure to be a useful and an
attractive alternative method to current linear-type synthesis
of 4-thiazolidinone.
ß 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.archpharm.com

Arch. Pharm. Chem. Life Sci. 2011, 344, 821–829
Efficient Regioselective Three-Component Domino Synthesis . . .
825
Experimental section
(4–14 days), conidia were harvested by flooding the colonies
with a sterile solution of 0.85% NaCl and 0.05% Tween 80 in
sterile distilled water. Inocula were prepared with a hemocy-
tometer for counting and were then diluted with RPM1 1640
medium to obtain a final inoculum size of approximately
0.5 ꢃ 103 to 2.5 ꢃ 103 CFU/mL. The inoculum size was veri-
fied by plating an aliquot of the inoculum. The cultures were
incubated at 308C for 48 to 72 h or until growth in the
control tube was visible.
Biology
Mycobacterium tuberculosis susceptibility testing
The compounds were tested against M. tuberculosis H37Rv in
BACTEC 12B medium using a fluorometric broth microdilu-
tion assay, the Microplate Alamar Blue Assay (MABA) [32].
Compounds were initially assessed at 6.25 mg/mL, and those
effecting a reduction in fluorescence of at least 90% relative
to untreated cultures were further evaluated for MIC by
testing at lower concentrations. The MIC was defined as
the lowest concentration of compound effecting a reduction
of ꢂ90% of the relative fluorescence units relative to a control
culture. Rifampin (control antibiotic) is typically used to treat
Mycobacterium infections, including tuberculosis and
Hansen’s disease.
Synthetic protocols
Melting ranges (8C) were recorded on a Fischer-Johns appar-
atus (Fischer-Scientific, Pittsburgh, PA, USA) and were uncor-
rected. IR spectra were recorded on a Schimadzu IR-470
spectrometer (Schimadzu, Kyoto, Japan). 1H-NMR and
13C-NMR spectra were recorded on a Varian EM-360 L NMR
spectrometer at 300 MHz and 75 MHz, respectively. (Varian
Inc., Palo Alto, CA, USA) Chemicals (Aldrich, Merck,
Whitehouse Station, NJ, USA). Chemical shifts are expressed
in d-values (ppm) relative to TMS as internal standard and
using CD3Cl as solvent. High resolution MS were determined
with a JEOL JMS-SX 102A spectrometer. Microanalytical data
(C, N, H) agreed with the proposed structures within þ0.4% of
the theoretical values. Thin layer chromatography was per-
formed on precoated silica gel plates (Kieselgel, 0.25 mm,
60G F 254, Merck). A developing solvent system of chloro-
form/methanol (8:2) was used and the spots were detected by
ultraviolet light.
Antifungal test organisms
The fungi used in this study for all the compounds in Table 1
included two reference strains, C. albicans A39 and A. fumigatus
(strain 168.95). Expanded studies on 1s-p employed the fungi
listed in Table 2.
Medium
Antifungal susceptibility testing was performed with RPMI
1640 medium (Sigma Chemical Co., St. Louis, MO) with glu-
tamine, but without sodium bicarbonate, and was buffered
at pH 7.0 with 0.165 M morpholinopropanesulfonic acid.
Antifungal in-vitro susceptibility testing
Synthesis of 3-(substituted)-1H-1,2,4-triazole 5-amine
(3a,b) [28]
Experiments for determination of MICs of yeasts were per-
formed by the broth macrodilution method according to the
recommendations of the National Committee for Clinical
Laboratory Standards [32]. The only difference compared to
the standardized method was the choice of drug dilutions,
which ranged from 100 to 0.09 mg/mL. Briefly, this method
specifies the use of an inoculum grown at 358C and adjusted
to a concentration of 0.5 ꢃ 103 to 2.5 ꢃ 103 CFU/mL.
Readings were taken at 48 h for all yeasts except for
C. neoformans, for which the results are interpreted at 72 h.
The MIC was defined as the culture with the lowest drug
concentration in which a visual turbidity less than or equal
to 80% inhibition compared to that produced by the growth
control tube was observed.
To a solution of N-cyanocarbonimidodithioic acid dimethyl
ester (5) (36.5 g, 0.25 mol) in 100 mL MeCN was added mor-
pholine or 4-methylpiprazine (0.25 mmol). The mixture was
refluxed for 2 h, cooled and 15 mL NH2NH2 ꢀ H2O was added
and refluxed for additional 5 h. The solvent was evaporated
under vacuum to give solid products. Recrystallization from
appropriate solvent afforded 3.
3-(1-Morpholin-4-yl)-1H-1,2,4-triazol-5-amine (3a)
Yield (89%), m.p. 167–1688C (2-PrOH). 1H-NMR (300 MHz,
CDCl3): d 3.23 (t, J ¼ 4.8 Hz, 4H, H-3 & 5-mor), 3.70
(t, J ¼ 4.8 Hz, 4H, H-2 & 6-mor), 5.65 (brs, 2H, NH2), 9.96
(br, 1H, NH). 13C-NMR (75 MHz, CDCl3): d 46.6, 66.2,
The minimum fungicidal concentration (MFC) was deter-
mined by plating 100-mL aliquots from tubes showing
complete inhibition of growth on Sabouraud agar plates.
The lowest drug concentration that yielded three or fewer
colonies was recorded as the MFC.
158.6,163.4. IR (CHCl3): n ¼ 3220, 3130, 1630 cmꢄ1
.
3-(4-Methylpiprazin-1-yl)-1H-1,2,4-triazol-5-amine (3b)
Yield (90%), m.p. 89–918C (MeOH). 1H-NMR (300 MHz, CDCl3):
d 2.33 (t, J ¼ 6.2 Hz, 4H, H-3 & 5-pip), 3.35 (t, J ¼ 6.2 Hz, 4H,
H-2 & 6-pip), 5.80 (brs, 2H, NH2), 11.0 (br, 1H, NH). 13C-NMR
(75 MHz, CDCl3): d 45.6, 45.4, 58.2, 159.3, 163.9. IR (CHCl3):
Moulds were tested by the same method [33], but with the
following modifications. Isolates were grown on Sabouraud
dextrose agar at 308C; after adequate sporulation occurred
n ¼ 3230, 3135, 1653 cmꢄ1
.
ß 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.archpharm.com

826
S. A. El Bialy et al.
Arch. Pharm. Chem. Life Sci. 2011, 344, 821–829
Synthesis of 3-[(3-morpholin-4-yl)-1H-1,2,4-triazol-5-yl)]-2-
substituted phenyl-1,3-thiazolidin-4-one (1a–j)
5-Methyl-2-(4-methylphenyl)-3-[(3-morpholin-4-yl)-
1H-1,2,4-triazol-5-yl)]-1,3-thiazolidin-4-one (1d)
Yield (88%), m.p. 179–1808C (Hex/EtOAc) as diastereomeric
mixture (cis/trans; 2:1).
To a solution of 5-amino-3-(1-morpholino)-1H-[1,2,4]triazole
3a (1.69 g, 10 mmol) in toluene (50 mL) was added aromatic
aldehydes (10 mmol), a-mercaptoacids (10 mmol) and 1 g
cis-Isomer: 1H-NMR (300 MHz, CDCl3): d 1.61 (d, J ¼ 6.9 Hz,
3H, CH3), 2.33 (s, 3H, CH3), 3.24 (t, J ¼ 4.2 Hz, 4H, H-3 &
5-mor), 3.68–3.74 (m, 4H, H-2 & 6-mor), 4.25 (q, J ¼ 6.9 Hz,
1H, H-5), 6.29 (s, 1H, H-2), 7.13 (d, J ¼ 8 Hz, 2H, H-Ar), 7.21
(d, J ¼ 8Hz, 2H, H-Ar)
˚
molecular sieves (4 A). The mixture was heated at 1008C
for 8 h. The solution was filtered and evaporated under
vacuum. H2O (100 mL) was added and the mixture was
extracted with AcOEt (2 ꢃ 250 mL) and the organic layer
was dried (Na2SO4) and solvent was evaporated under
vacuum to give solid residues. Recrystallization from an
appropriate solvent gave 1a–j.
trans-Isomer: 1H-NMR (300 MHz, CDCl3): d 1.71 (d, J ¼ 6.9 Hz,
3H, CH3), 4.09 (q, J ¼ 6.9 Hz, 1H, H-5). 13C-NMR (75 MHz, CDCl3):
d 17.3, 21.2, 40.9, 46.7, 46.7, 59.8, 66.3, 66.6, 125.7, 126.5, 129.3,
129.5, 137.2, 138.5, 157.4, 158.5, 184.3. IR (CHCl3):
n ¼ 1706 cmꢄ1. MS m/z ¼ 359 (100, Mþ), 149 (35.7) 135
(17.2). HR-MS; 359.1419 for C17H21N5O2S (359.1416).
3-[(3-Morpholino-1H-1,2,4-triazol-5-yl)]-2-phenyl-1,3-
thiazolidin-4-one (1a)
1
Yield (83%), m.p. 201–2038C (Hex/EtOAc). H-NMR (300 MHz,
CDCl3): d 3.25 (dt, J ¼ 3, 4.7 Hz, 4H, H-3 & 5-mor), 3.71
(t, J ¼ 4.7 Hz, 4H, H-2 & 6-mor), 3.77 (d, J ¼ 16.8 Hz, 1H, H-
5), 4.06 (dd, J ¼ 1.3, 16.8 Hz, 1H, H-5), 6.38 (d, J ¼ 1.3 Hz, 1H,
H-2), 7.29–7.34 (m, 5H, H-Ar). 13C-NMR (75 MHz, CDCl3): d 39.8,
46.7, 46.6, 59.8, 66.3, 66.5, 126.4, 126.6, 129.3, 129.5, 137.3,
138.5, 184.2, 196.9. IR (CHCl3): n ¼ 1706 cmꢄ1. MS m/z ¼ 331
(100, Mþ). HR-MS; 331.1117 for C15H17N5O2S (331.1119).
2-(4-Chlorophenyl)-3-[(3-morpholin-4-yl)-1H-1,2,
4-triazol-5-yl)1,3-thiazolidin-4-one (1e)
1
Yield (79%), m.p. 202–2038C (Hex/EtOAc). H-NMR (300 MHz,
CDCl3): d 3.25 (dt, J ¼ 2.1, 5.1 Hz, 4H, H-3 & 5-mor), 3.74
(t, J ¼ 5.1 Hz, 4H, H-2 & 6-mor), 3.79 (d, J ¼ 16.5 Hz, 1H,
5-H1), 4.03 (dd, J ¼ 1.4, 16.5 Hz, 1H, H-5), 6.34 (d,
J ¼ 1.2 Hz, 1H, H-2), 7.25–7.33 (m, 4H, H-Ar) ppm; 13C-NMR
(75 MHz, CDCl3): d 34.7, 46.6, 59.8, 65.7, 66.3, 127.5, 129.0,
134.6, 138.7, 157.3, 158.6, 171.7 ppm; IR (CHCl3):
n ¼ 1706 cmꢄ1. MS m/z ¼ 367 (38.7, Mþþ2), 365 (100,
Mþ), 135 (47.8). HR-MS; 365.0718 for C15ClH16N5O2S
(365.0713).
5-Methyl-3-[(3-morpholin4-yl)-1H-1,2,4-triazol-5-yl)]-2-
phenyl-1,3-thiazolidin-4-one (1b)
Yield (86%), m.p. 179–1818C (Hex/EtOAc) as diastereomeric
mixture (cis/trans; 2:1).
cis-Isomer: 1H-NMR (300 MHz, CDCl3): d 1.62 (d, J ¼ 6.9 Hz,
3H, CH3), 3.25 (dt, J ¼ 1.2, 9.6 Hz, 4H, H-3 & 5-mor), 3.82
(t, J ¼ 9.6 Hz, 4H, H-2 & 6-mor), 4.35 (dq, J ¼ 0.6, 6.9 Hz,
1H, H-5), 6.31 (s, 1H, H-2), 7.37–7.25 (m, 5H, H-Ar).
trans-Isomer: 1H NMR (300 MHz, CDCl3): d 1.71 (d, J ¼ 6.9 Hz,
3H, CH3), 3.20 (d, J ¼ 15 Hz, 4H, H-3 & 5-mor), 3.73
(t, J ¼ 15 Hz, 4H, H-2 & 6-mor), 4.11 (q, J ¼ 6.9 Hz, 1H, H-5)
ppm; 13C-NMR (75 MHz, CDCl3): d 23.3, 44.9, 46.7, 46.7, 59.8,
66.3, 66.6, 125.9, 126.5, 129.3, 129.5, 137.2, 158.5,
159.4 184.3. IR (CHCl3): n ¼ 1709 cmꢄ1; MS m/z ¼ 345
(100, Mþ); HR-MS; 345.1254 for C16H19N5O2S
(345.1259).
2-(4-Chlorophenyl)-5-methyl-3-[(3-morpholin-4-yl)-
1H-1,2,4-triazol-5-yl)]-1,3-thiazolidin-4-one (1f)
Yield (81%), m.p. 219–2208C (Hex/EtOAc) as diastereomeric
mixture (cis/trans; 5:1).
cis-Isomer: 1H-NMR (300 MHz, CDCl3): d 1.71 (d, J ¼ 6.9 Hz,
3H, CH3), 3.19–3.26 (m, 4H, H-3 & 5-mor), 3.69–3.74 (m, 4H, H-
2 & 6-mor), 4.11 (q, J ¼ 6.9 Hz, 1H, H-5), 6.26 (s, 1H, H-2), 7.47–
1
738 (m, 4H, H-Ar). trans-Isomer: H-NMR (300 MHz, CDCl3): d
1.62 (d, J ¼ 6.9 Hz, 3H, CH3), 3.9–3.26 (m, 4H, H-3 & 5-mor),
3.69–3.74 (m, 4H, 2 H-2 & 6-mor), 4.28 (q, J ¼ 6.9 Hz, 1H, H-5),
6.26 (s, 1H, H-2), 7.47–7.38 (m, 4H, H-Ar). 13C NMR (75 MHz,
CDCl3): d 21.7, 42.7, 46.6, 59.8, 66.3, 127.5, 129.0, 134.6,
138.8, 157.4, 158.5, 171.7. IR (CHCl3): n ¼ 1706 cmꢄ1. MS
m/z ¼ 381 (38.5, Mþþ2), 379 (100, Mþ), 135. HR-MS;
379.0867 for C16ClH18N5O2S (379.0869).
2-(4-Methylphenyl)-3-[(3-morpholin-4-yl)-1H-1,2,4-triazol-
5-yl)]-1,3-thiazolidin-4-one (1c)
1
Yield (91%), m.p. 158–1598C (Hex/EtOAc). H-NMR (300 MHz,
CDCl3): d 2.33 (s, 3H, CH3), 3.26 (dt, J ¼ 1.8, 4.8 Hz, 4H, H-3 &
5-mor), 3.72 (t, J ¼ 4.8 Hz, 4H, H-2 & 6-mor), 3.76 (d, J ¼ 16.5,
1H, H-5), 4.06 (dd, J ¼ 1.2, 16.5 Hz, 1H, H-5), 6.36 (s, 1H, H-2),
7.14 (d, J ¼ 8.1 Hz, 2H, H-Ar), 7.02 (d, J ¼ 8.1 Hz, 2H, H-Ar).
13C-NMR (75 MHz, CDCl3): d 25.6, 33.8, 46.7, 46.7, 59.8, 66.3,
66.5, 123.2, 123.6, 129.3, 129.5, 137.3, 138.4, 157.4, 158.5,
184.2. IR (CHCl3): n ¼ 1706 cmꢄ1; MS m/z ¼ 345 (100, Mþ),
135 (57). HR-MS; 345.1260 for C16H19N5O2S (345.1259).
2-(3,4-Dimethoxyphenyl)-3-[(3-morpholin-4-yl)-1H-1,2,
4-triazol-5-yl)]-1,3-thiazolidin-4-one (1g)
1
Yield (73%), m.p. 148–1508C (Hex/EtOAc). H-NMR (300 MHz,
CDCl3): d 3.27 (dt, J ¼ 1.8, 5.0 Hz, 4H, H-3 & 5-mor), 3.73
(t, J ¼ 5.0 Hz, 4H, H-2 & 6-mor), 3.77 (d, J ¼16.5 Hz, 1H, H-
5), 3.89, 3.90 (s, 3H each, 2 MeO), 4.04 (dd, J ¼ 1.2, 16.5 Hz, 1H,
H-5), 6.35 (d, J ¼1.2 Hz, 1H, H-2), 6.77–6.80 (m, 1H, H-Ar),
ß 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.archpharm.com

Arch. Pharm. Chem. Life Sci. 2011, 344, 821–829
Efficient Regioselective Three-Component Domino Synthesis . . .
827
6.86–6.88 (m, 2H, H-Ar). 13C-NMR (75 MHz, CDCl3): d 32.9,
aromatic aldehydes (10 mmol), a-mercaptoacids (10 mmol)
˚
and 1 g molecular sieves (4 A). The mixture was heated at
46.6, 55.9, 55.9, 62.4, 65.8, 66.3, 115.7, 117.9, 122.3, 132.4,
149.2, 149.4, 157.4, 158.5, 171.9. IR (CHCl3): n ¼ 1706 cmꢄ1
.
1008C for 8 h. The solution was filtered, evaporated under
vacuum, dissolved in H2O (100 mL) and the mixture was
extracted with AcOEt (2 ꢃ 250 mL) and the organic layer
was dried (Na2SO4) and solvent was evaporated under
vacuum to give solid residues. Recrystallization from an
appropriate solvent gave 1k-t.
MS m/z ¼ 391 (100, Mþ), 165 (31.4). HR-MS; 391.1308
for C17H21N5O2S (391.1314).
2-(3,4-Dimethoxyphenyl)-5-methyl-3-[(3-morpholin-4-yl)-
1H-1,2,4-triazol-5-yl)]-1,3-thiazolidin-4-one (1h)
Yield (79%), m.p. 193–1948C (Hex/EtOAc) as diastereomeric
mixture (cis/trans; 1:1).
3-[3-(4-Methylpiperazin-1-yl)-1H-1,2,4-triazol-5-yl]-
2-phenyl-1,3-thiazolidin-4-one (1k)
cis-Isomer: 1H-NMR (300 MHz, CDCl3): d 1.62 (d, J ¼ 6.9 Hz,
3H, CH3), 3.22–3.30 (m, 4H, H-3 & 5-mor), 3.72 (q, J ¼ 9.6 Hz,
4H, H-2 & 6-mor), 3.86 (s, 6H, 2 OMe), 4.10 (q, J ¼ 9.6 Hz, 1H,
H-5), 6.29 (d, J ¼ 2.4 Hz, 1H, H-2), 6.76–6.89 (3H, m, H-Ar).
trans-Isomer: 1H-NMR (300 MHz, CDCl3): d 1.72 (d, J ¼ 6.9 Hz,
3H, CH3), 4.26 (q, J ¼ 6.9 Hz, 1H, H-5). 13C-NMR (75 MHz, CDCl3):
d 21.7, 42.2, 46.1, 55.2, 55.3, 62.0, 66.2, 66.3, 116.6, 117.3, 122.2,
131.3, 147.8, 148.6, 157.3, 158.4, 171.8. IR (CHCl3):
n ¼ 1706 cmꢄ1. MS m/z ¼ 405 (100, Mþ), 179 (24.2). HR-
MS; 405.1473 for C18H23N5O2S (405.1470).
1
Yield (69%), m.p. 168–1708C (Hex/EtOAc); H-NMR (300 MHz,
CDCl3): d 2.28 (s, 3H, NMe), 2.41 (t, J ¼ 5.1 Hz, 4H, H-3 &
5-pipzin), 3.29 (dt, J ¼ 1.8, 3.6 Hz, 4H, H-2 & 6-pipzin), 3.76
(d, J ¼ 16.5 Hz, 1H, H-5), 4.04 (dd, J ¼ 1.2, 16.5 Hz, 1H, H-5),
6.39 (d, J ¼ 1.2 Hz, 1H, H-2), 7.31–7.33 (m, 5H, H-Ar). 13C-NMR
(75 MHz, CDCl3): d 32.7, 46.2, 46.3, 54.3, 62.3, 78.8, 125.9,
128.7, 198.8, 140.2, 171.9, 184.3, 184.3. IR (CHCl3):
n ¼ 1706 cmꢄ1. MS m/z ¼ 344 (56.5, Mþ), 274 (100) 200
(61.5), 71 (82.1), 70 (30.7), 43 (60.2). HR-MS; 344.1417
for C16H20N6OS (344.1419).
2-(Benzo[d][1,3]dioxol-6-yl)-3-[(3-morpholin-4-yl)-
1H-1,2,4-triazol-5-yl)]-1,3-thiazolidin-4-one (1i)
5-Methyl-3-[3-(4-methylpiperazin-1-yl)-1H-1,2,4-triazol-
5-yl]-2-phenyl-1,3-thiazolidin-4-one (1l)
1
Yield (69%), m.p. 191–1928C (Hex/EtOAc). H-NMR (300 MHz,
CDCl3): d 3.28 (dt, J ¼ 2.0, 3.6 Hz, 4H, H-3 & 5-mor), 3.74
(t, J ¼ 3.6 Hz, 4H, H-2 & 6-mor), 3.83 (d, J ¼ 16.5 Hz, 1H,
H-5), 4.05 (dd, J ¼ 1.3, 16.5 Hz, 1H, H-5), 5.96 (d, J ¼ 1.2 Hz),
2H, 6.31 (s, 1H, H-2), 6.72–6.82 (m, 3H, H-Ar). 13C-NMR (75 MHz,
CDCl3): d 35.6, 46.7, 65.7, 66.5, 67.0, 101.6, 117.9, 116.4, 125.8,
132.7, 149.7, 148.9, 157.8, 158.8, 172.4. IR (CHCl3):
n ¼ 1706 cmꢄ1. MS m/z ¼ 375 (100, Mþ), 150 (15.9). HR-
MS; 375.1011 for C16H17N5O2S (375.1001).
Yield (65%), m.p. 159–1608C (Hex/EtOAc).
cis-Isomer: 1H-NMR (300 MHz, CDCl3): d 1.61 (d, J ¼ 6.9 Hz,
3H, CH3), 2.28 (s, 3H, NMe), 2.42 (t, J ¼ 5.1 Hz, 4H, H-3 &
5-pipzin), 3.31 (dd, J ¼ 4.2, 6.3 Hz, 4H, H-2 & 6-pipzin), 4.24
(q, J ¼ 6.9 Hz, 1H, H-5), 6.32 (d, J ¼1.2 Hz, 1H, H-2), 7.28–7.34
(m, 5H, H-Ar);
1
trans-Isomer: H-NMR (300 MHz, CDCl3): d 1.70 (d, J ¼ 6.9,
3H, CH3), 2.27 (s, 3H, NMe), 4.10 (q, J ¼ 6.9 Hz, 1H, H-5).
13C-NMR (75 MHz, CDCl3): d 17.3, 20.4, 40.9, 42.4, 46.2,
46.2, 46.3, 54.3, 54.3, 59.9, 60.9, 46.3, 54.3, 54.3, 59.9, 60.9,
125.8, 126.6, 128.8, 128.6, 140.9, 125.8, 126.6, 128.8, 128.6,
145.2, 184.3. IR (CHCl3): n ¼ 1706 cmꢄ1; MS m/z ¼ 358
(51.4, Mþ), 288 (100), 200 (59.3), 71 (67.8), 70 (24.3), 43
(46.9). HR-MS; 358.1578 for C17H22N6OS (358.1576).
2-(Benzo[d][1,3]dioxol-6-yl)-5-methyl-3-[(3-morpholin-
4-yl)-1H-1,2,4-triazol-5-yl)]-1,3-thiazolidin-4-one (1j)
Yield (71%), m.p. 182–1838C (Hex/EtOAc) as diastereomeric
mixture (cis/trans; 1:1).
cis-Isomer: 1H-NMR (300 MHz, CDCl3): d 1.61 (d, J ¼ 6.9 Hz,
3H, CH3), 3.22–3.31 (m, 4H, H-3 & 5-mor), 3.70–3.75 (m, 4H,
H-2 & 6-mor), 4.09 (q, J ¼ 6.9 Hz, 1H, H-5), 5.96 (d, J ¼ 1.2 Hz),
6.24 (s, 1H, H-2), 6.70–6.86 (m, 3H, H-Ar).
trans-Isomer: 1H-NMR (300 MHz, CDCl3): d 1.72 (d, J ¼ 6.9 Hz,
3H, CH3), 4.25 (q, J ¼ 6.9 Hz, 1H, H-5). 13C-NMR (75 MHz, CDCl3):
d ¼ 21.8, 44.4, 46.5, 65.2, 66.3, 66.7, 101.1, 117.2, 116.2, 125.2,
131.6, 148.6, 148.9, 157.9, 158.9, 172.4. IR (CHCl3):
n ¼ 1706 cmꢄ1. MS m/z ¼ 389 (100, Mþ), 165 (18.8). HR-
MS; 389.1153 for C17H19N5O2S (389.1157).
2-Methylphenyl-3-[3-(4-methylpiperazin-1-yl)-1H-1,2,4-
triazol-5-yl]-1,3-thiazolidin-4-one (1m)
1
Yield (67%), m.p. 149–1508C (Hex/EtOAc). H-NMR (300 MHz,
CDCl3): d 2.29 (s, 3H, NMe), 2.33 (s, 3H, CH3), 2.42 (t, J ¼ 5.1 Hz,
4H, H-3 & 5-pipzin), 3.31 (t, J ¼5.1 Hz, 4H, H-2 & 6-pipzin),
3.75 (d, J ¼ 16.5, 1H, H-5), 4.04 (dd, J ¼ 1.2, 16.5 Hz, 1H, H-5),
6.37 (s, 1H, H-2), 7.13 (d, J ¼ 8.4 Hz, 2H, H-Ar), 7.21 (d,
J ¼ 8.4 Hz, 2H, H-Ar). 13C-NMR (75 MHz, CDCl3): d 21.2,
32.8, 46.3, 54.4, 62.2, 115.3, 125.9 ꢃ 2, 129.4 ꢃ 2, 137.2,
138.6, 171.9, 184.3, 197.0. IR (CHCl3): n ¼ 1706 cmꢄ1; MS
m/z ¼ 358 (56.1, Mþ), 288 (100), 214 (58.0), 71 (68.6),
70 (25.1), 43 (48.4). HR-MS; 358.1571 for C17H22N6OS
(358.1576).
Synthesis of 3-[3-(4-methylpiperazin-1-yl)-1H-1,2,4-triazol-
5-yl]-2-substituted phenyl-1,3-thiazolidin-4-one (1k–t)
To a solution of 5-amino-3-(4-methylpiperazin-1-yl)-1H-[1,2,4]-
triazole 3b (1.82 g, 10 mmol) in toluene (50 mL) was added
ß 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.archpharm.com

828
S. A. El Bialy et al.
Arch. Pharm. Chem. Life Sci. 2011, 344, 821–829
5-Methyl-2-methylphenyl-3-[3-(4-methylpiperazin-1-yl)-
1H-1,2,4-triazol-5-yl]-1,3-thiazolidin-4-one (1n)
OCH3), 4.03 (dd, J ¼ 1.5, 16.5 Hz, 1H, H-5), 6.38
(d, J ¼ 1.5 Hz, 1H, H-2), 6.69–6.89 (m, 3H, H-Ar). 13C-NMR
(75 MHz, CDCl3): d 32.6, 46.1, 45.6, 46.6, 54.8, 55.8, 55.9,
62.7, 109.2, 110.6, 118.5, 132.9, 149.4, 171.5, 184.7, 197.2.
IR (CHCl3): n ¼ 1707 cmꢄ1; MS m/z ¼ 404 (65.9, Mþ), 332
(100), 244 (41.9), 71 (73.4), 70 (27.0), 43 (53.8), 42 (27.4).
HR-MS; (404.1633) for C18H24N6O3S (404.1631).
Yield (65%), m.p. 154–1568C (Hex/EtOAc).
cis-Isomer: 1H-NMR (300 MHz, CDCl3): d 1.72 (d, J ¼ 7.2 Hz,
3H, CH3), 2.28 (s, 3H, NMe), 2.32 (s, 3H, CH3), 2.39–2.43 (m, 4H,
H-3 & 5-pipzin), 3.25–3.30 (m, 4H, H-2 & 6-pipzin), 4.12
(q, J ¼ 7.2 Hz, 1H, H-5), 6.30 (s, 1H, H-2), 7.12 (t, J ¼ 8.1 Hz,
2H, H-Ar), 7.21 (t, J ¼ 8.1 Hz, 2H, H-Ar) ppm;
trans-Isomer: 1H-NMR (300 MHz, CDCl3): d 1.62 (3H, d,
J ¼ 7.2 Hz), 2.29 (3H, s, NMe), 2.33 (3H, s), 4.24 (1H, q,
J ¼ 7.2 Hz, 5-H1). 13C-NMR (75 MHz, CDCl3): d 20.4, 21.2,
42.4, 46.2, 46.3, 54.2, 54.3, 60.8, 125.7, 126.5 ꢃ 2,
129.3 ꢃ 2, 129.5, 174.8, 184.3, 197.6. IR (CHCl3):
n ¼ 1706 cmꢄ1; MS m/z ¼ 372 (50.3, Mþ), 302 (100), 214
(54.5), 71 (59.2), 70 (21.0), 43 (43.2). HR-MS; 372.1730
for C18H24N6OS (372.1732).
2-(3,4-Dimethoxyphenyl)-5-methyl-3-[3-(4-methylpiperazin-
1-yl)-1H-1,2,4-triazol-5-yl]-1,3-thiazolidin-4-one (1r)
Yield (79%), m.p. 138–1398C (Hex/EtOAc).
cis-Isomer: 1H-NMR (300 MHz, CDCl3): d 1.73 (d, J ¼ 7.2 Hz,
3H, CH3), 2.29 (s, 3H, NMe), 2.42 (t, J ¼ 5.1 Hz, 4H, H-3 &
5-pipzin), 3.34 (t, J ¼ 5.1 Hz, 4H, H-2 & 6-pipzin), 3.85
(s, 6H, 2OMe), 4.12 (q, J ¼ 7.2 Hz, 1H, H-5), 6.28
(d, J ¼ 1.5 Hz, 1H, H-2), 6.77–6.92 (m, 3H, H-Ar) ppm;
trans-Isomer: 1H-NMR (300 MHz, CDCl3):
d
1.63
2-(4-Chlorophenyl)-3-[3-(4-methylpiperazin-1-yl)-1H-1,2,
4-triazol-5-yl]-1,3-thiazolidin-4-one (1o)
(d, J ¼ 7.2 Hz, 3H, CH3), 2.31 (s, 3H, NMe), 4.23
(q, J ¼ 7.2 Hz, 1H, H-5). 13C-NMR (75 MHz, CDCl3): d 21. 2,
42.7, 46.1, 45.7, 54.6, 55.3, 62.0, 66.2, 66.3, 116.6, 117.3, 122.2,
131.3, 147.8, 148.6, 157.3, 158.4, 171.8. IR (CHCl3):
n ¼ 1707 cmꢄ1; MS m/z ¼ 418 (63.1, Mþ), 332 (100), 244
(44.5), 71 (76.7), 70 (24.0), 43 (51.8), 42 (25.1). HR-MS;
(418.1785) for C18H22N6O3S (418.1787).
1
Yield (77%), m.p. 139–1408C (Hex/EtOAc); H-NMR (300 MHz,
CDCl3): d 2.29 (s, 3H, NMe), 2.43 (t, J ¼ 5.1 Hz, 4H, H-3 &
5-pipzin), 3.30 (t, J ¼ 1.2, 5.1 Hz, 4H, H-2 & 6-pipzin), 3.78
(d, J ¼ 16.5 Hz, 1H, H-5), 4.02 (d, J ¼ 16.5 Hz, 1H, H-5), 6.35
(d, J ¼ 1.2 Hz, 1H, H-2), 7.25–7.33 (4H, m, H-Ar). 13C-NMR
(75 MHz, CDCl3): d 34.7, 46.6, 59.8, 65.7, 66.3, 127.5, 129.0,
134.6, 138.7, 157.3, 158.6, 171.7. IR (CHCl3): n ¼ 1709 cmꢄ1
.
2-(Benzo[d][1,3]dioxol-6-yl)-3-[3-(4-methylpiperazin-1-yl)-
1H-1,2,4-triazol-5-yl]-1,3-thiazolidin-4-one (1s)
MS m/z ¼ 380 (14.6, Mþþ2), 378 (38.6, Mþ), 308 (71.4),
234 (46.9), 71 (100), 70 (47.9), 43 (82.1), 42 (41.9). HR-MS;
378.1032 for C16ClH19N6OS (378.1029).
1
Yield (73%), m.p. 155–1578C (Hex/EtOAc); H-NMR (300 MHz,
CDCl3): d 2.30 (s, 3H, NMe), 2.11 (t, J ¼ 5.1 Hz, 4H, H-3 & 5-
pipzin), 3.26 (t, J ¼ 5.1 Hz, 4H, H-2 & 6-pipzin), 3.72
(d, J ¼ 16.5 Hz, 1H, H-5), 4.01 (d, J ¼ 16.5 Hz, 1H, H-5), 5.94
(s, 2H, OCH2O), 6.27 (d, J ¼ 2.5 Hz, 1H, H-2), 6.70–6.86 (m, 3H,
H-Ar). 13C-NMR (75 MHz, CDCl3): d 33.6, 45.5, 46.7, 54.7, 56.1,
65.7, 110.2, 112.6, 113.8, 122.8, 132.7, 148.4, 149.4, 159.8,
161.8, 171.4. IR (CHCl3): n ¼ 1708. MS m/z ¼ 388 (68.3, Mþ),
332 (100), 244 (46.2), 71 (77.8), 70 (25.9), 43 (55.1), 42
(26.6). HR-MS; (388.1320) for C18H22N6O3S (388.1318).
2-(4-Chlorophenyl)-5-methyl-3-[3-(4-methylpiperazin-1-yl)-
1H-1,2,4-triazol-5-yl]-1,3-thiazolidin-4-one (1p)
Yield (73%), m.p. 168–1708C (Hex/EtOAc).
cis-Isomer: 1H-NMR (300 MHz, CDCl3): d 1.61 (d, J ¼ 6.9 Hz,
3H, CH3), 2.29 (s, 3H, NMe), 2.38–2.45 (m, 4H, H-3 & 5-pipzin),
3.25–3.33 (m, 4H, H-2 & 6-pipzin), 4.18 (q, J ¼ 6.9 Hz, 1H, H-5),
6.29 (d, J ¼ 2.4 Hz, 1H, H-2), 7.18–7.32 (m, 4H, H-Ar);
trans-Isomer: 1H-NMR (300 MHz, CDCl3): d 1.69 (d, J ¼ 6.9 Hz,
3H, CH3), 2.28 (s, 3H, NMe), 4.11(q, J ¼ 6.9 Hz, 1H, H-5). 13C-NMR
(75 MHz, CDCl3): d 21.5, 42.7, 45.7, 46.8, 60.1, 66.2, 127.1, 129.3,
134.7, 138.9, 157.6, 158.5, 171.9 ppm; IR (CHCl3):
2-(Benzo[d][1,3]dioxol-6-yl)-5-methyl-3-[3-(4-
methylpiperazin-1-yl)-1H-1,2,4-triazol-5-yl]-1,3-thiazolidin-
4-one (1t)
n ¼ 1710 cmꢄ1
.
MS m/z ¼ 394 (13.8, Mþþ2), 392
Yield (70%), m.p. 129–11308C (Hex/EtOAc).
(36.4, Mþ), 322 (73.2), 234 (48.9), 71 (100), 70 (45.7), 43
(81.7), 42 (39.4). HR-MS; 392.1188 for C17ClH21N6OS
(392.1186).
cis-Isomer: 1H-NMR (300 MHz, CDCl3): d 1.60 (d, J ¼ 6.9 Hz,
3H, CH3), 2.30 (s, 3H, NMe), 2.12 (t, J ¼ 5.1 Hz, 4H, H-3 &
5-pipzin), 3.24 (t, J ¼ 5.1 Hz, 4H, H-2 & 6-pipzin), 4.27
(q, J ¼ 6.9 Hz, 1H, H-5) 5.92 (s, 2H, OCH2O), 6.27
(d, J ¼ 2.5 Hz, 1H, H-2), 6.70–6.86 (m, 3H, H-Ar);
2-(3,4-Dimethoxyphenyl)-3-[3-(4-methylpiperazin-1-yl)-
1H-1,2,4-triazol-5-yl]-1,3-thiazolidin-4-one (1q)
trans-Isomer: 1H-NMR (300 MHz, CDCl3): d 1.71 (d, J ¼ 6.9 Hz,
3H, CH3), 2.29 (s, 3H, NMe), 4.09 (, J ¼ 6.9 Hz, 1H, H-5) ppm;
13C-NMR (75 MHz, CDCl3): d 21.8, 42.4, 45.5, 46.5, 54.7, 63.2,
110.2, 112.1, 117.2, 122.2, 131.6, 148.6, 148.9, 158.9, 161.9,
174.1. IR (CHCl3): n ¼ 1706; MS m/z ¼ 402 (70.3, Mþ), 332
1
Yield (78%), m.p. 122–1248C (Hex/EtOAc); H-NMR (300 MHz,
CDCl3): d 2.29 (s, 3H, NMe), 2.43 (t, J ¼ 5.1 Hz, 4H, H-3 &
5-pipzin), 3.33 (t, J ¼ 5.1 Hz, 4H, H-2 & 6-pipzin), 3.72
(d, J ¼ 16.5 Hz, 1H, H-5), 3.86 (s, 3H, OCH3), 3.87 (s, 3H,
ß 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.archpharm.com

Arch. Pharm. Chem. Life Sci. 2011, 344, 821–829
Efficient Regioselective Three-Component Domino Synthesis . . .
829
[16] C. V. Kavitha, B. Basappa, S. N. Swamy, K. Mantelingu,
S. Doreswamy, M. A. Sridhar, J. S. Prasad, K. S. Rangappa,
Bioorg. Med. Chem. 2006, 14, 2290–2299.
(100), 244 (46.2), 71 (76.4), 70 (27.8), 43 (57.5), 42 (23.6).
HR-MS; 402.1467 for C18H22N6O3S (402.1474).
[17] S. Giri, A. K. Shukla, K. Nizamuddin, J. Indian Pharm. Sci. 1990,
52, 108–110.
We are grateful to Prof. S. Bayomi for discussions and to the Fulbright for
financial support to publish this work.
[18] N. Cesur, Z. Cesur, N. Ergenc, M. Uzun, M. Kiraz,
O. Kasimoglu, D. Kaya, Arch. Pharm. 1994, 327, 271–272.
The authors have declared no conflict of interest.
[19] S. Ozkirimli, F. Kazan, Y. Tunali, J Enzyme Inhib. Med. Chem.
2009, 24, 447–452.
[20] A. R. Bhat, S. Shetty, J. Indian Pharm. Sci. 1987, 194–197.
References
[21] L. Bukowski, M. Janowiec, Z. Zwolska-Kwiek, Z. Andrzejczyk,
Pharmazie 1998, 53, 373–376.
[1] D. J. Abraham, D. P. Rotella, Burger’s Medicinal Chemistry, Drug
Discovery and Development, 7th ed, Vol. 7, John Wiley, New
York 2010.
[22] C. J. Andres, J. J. Bronson, S. V. D. Andrea, M. S. Deshpande,
P. J. Falk, K. A. Grant-Young, W. E. Harte, H. T. Ho, P. F. Misco,
J. G. Robertson, D. Stock, Y. Sun, A. W. Walsh, Biorg. Med.
Chem. Lett. 2000, 10, 715–717.
[2] (a) I. Ugi, A. Do¨mling, W. Ho¨rl, Endeavour 1994, 18, 115–122;
(b) R. W. Armstrong, A. P. Combs, P. A. Tempest, S. D. Brown,
T. A. Keating, Acc. Chem. Res. 1996, 29, 123–131; (c) S. L. Cui,
X. F. Lin, Y. G. Wang, J. Org. Chem. 2005, 70, 2866–2869.
[23] T. E. Benson, C. T. Walsh, J. M. Hogle, Biochemistry 1997, 36,
806–811.
[24] S. A. A. El Bialy, A. M. Abdelal, A. El Shorbagy, S. M. M. Kheira,
Arch. Pharm. Chem. Life Sci. 2005, 338, 38–43.
[3] S. L. Dax, J. J. Mc Nally, M. A. Yougman, Curr. Med. Chem. 1999,
6, 255–270.
[25] U. El-Ayaan, N. M. El-Metwally, M. M. Youssef, S. A. A. El Bialy,
Spectrochim. Acta, Part A 2007, 68, 1278–1286.
[4] (a) M. Plunket, J. Ellman, A. Sci. Am. 1997, 276, 68–73;
(b) S. L. Schreiber, Science 2000, 287, 1964–1969.
[26] S. A. A. El Bialy, M. Gouda, J. Heterocycl. Chem. 2011, published
online. DOI: 10.1002/jhet.634.
[5] (a) R. S. Varma, D. Kumar, Tetrahedron Lett. 1999, 40, 7665–
7669; (b) C. O. Kappe, D. Kumar, R. S. Varma, Synthesis 1999,
1799–1803.
[27] A. M. Khalil, M. A. Berghot, M. A. Gouda, S. A. A. El Bialy,
Monatsh. Chem. 2010, 141, 1353–1360.
[6] L. F. Tietze, Chem. Rev. 1996, 96, 115–136.
[28] J. Reiter, L. Pongo, T. Somorai, P. Dvortsak, J. Heterocycl. Chem.
1986, 23, 401–408.
[7] L. F. Tietze, U. Beifuss, Angew. Chem. Int. Ed. 1993, 32, 131–
163.
[29] K. C. Joshi, A. Dandia, N. Ahmed, Indian J. Chem, B 1989, 28,
639–641.
[8] L. F. Tietze, G. Brasche, K. M. Gericke, Domino Reactions in
Organic Synthesis, Wiley-VCH, Weinheim, Germany 2006.
[30] D. Anshu, K. Gupta, Phosphorus, Sulfur Silicon Relat. Elem. 1994,
97, 27–33.
[9] (a) A. Verma, S. K. Saraf, Eur. J. Med. Chem. 2008, 43, 897–905;
(b) W. Cunico, C. R. B. Gomes, W. T. Vellasco, Jr, Mini-Rev. Org.
Chem. 2008, 5, 336–344.
[31] (a) A. Dandia, R. Singh, S. Khaturia, C. Merienne, G. Morgant,
J Biorg. Med. Chem. 2006, 14, 2409 –2417;
A. Loupy,
[10] (a) P. Vicini, A. Gernikaki, K. Anastasia, M. Incerti, F. Zani,
Bioorg. Med. Chem. 2006, 14, 3859–3864; (b) K. Babaoglu, M. A.
Page, V. C. Jones, M. R. McNeil, C. Dong, J. H. Naismith, R. E.
Lee, Bioorg. Med. Chem. Lett. 2003, 13, 3227–3230.
(b) M. Rajopadhye, F. D. Popp, J. Heterocycl. Chem. 1987, 24,
1637 –1642; (c) P. J. Taylor, Spectrochim. Acta 1970, 26,
153–163; (d) P. J. Taylor, Spectrochim. Acta 1970, 26, 165–
194; (e) T. Srivastava, W. Haq, S. B. Katti, Tetrahedron 2002,
58, 7619 –2624; (f) R. K. Rawal, T. Srivastava, W. Haq, S. B.
Katti, J. Chem. Res. 2004, 368–369.
[11] D. Pandya, K. B. Nair, Pharmazie 1993, 48, 414–417.
[12] A. A. Geies, E. A. Bakhite, H. S. El-Kashef, Pharmazie 1998, 53,
686–690.
[32] L. Collins, S. G. Franzblau, Antimicrob. Agents Chemother. 1997,
41, 1004–1009.
[13] A. I. Eid, F. A. Ragab, S. L. El-Ansary, S. M. El-Gazayerly, F. E.
Mourad, Arch. Pharm. 1994, 327, 211–213.
[33] National Committee for Clinical Laboratory Standards,
Reference method for broth dilution susceptibility testing
of yeasts Document M27-T. Tentative standard, National
Committee for Clinical Laboratory Standards, Wayne, PA
1995.
[14] O. Ates, A. Kocabalkanli, G. Sanis-Otuk, A. C. Ekinci, A. Vidin,
Arzneim.-Forsch. 1997, 47, 1134–1138.
[15] G. Capan, N. Ulusoy, N. Ergenc, M. Kiraz, Montsh. Chem. 1999,
130, 1399–1407.
ß 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.archpharm.com